Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963481 · ClinicalTrials.gov registry record · Phase 2
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01963481 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 23 participants.
The verdict
NCT01963481, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial studies how well exemestane and cyclophosphamide work in treating patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and human epidermal growth factor receptor (HER)2-negative stage IV breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01963481
The ClinicalTrials.gov registry entry for NCT01963481 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT01963481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01963481 about?
NCT01963481 is a clinical study titled "Exemestane and Cyclophosphamide for Metastatic Breast Cancer". This phase II trial studies how well exemestane and cyclophosphamide work in treating patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and human epidermal growth factor receptor (HER)2-negative stage IV breast cancer.
What is the current status of trial NCT01963481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2013-09. Estimated completion is 2017-10-01.
What interventions are being tested in trial NCT01963481?
The interventions under investigation include: Cyclophosphamide (DRUG), Exemestane (DRUG).
Who is sponsoring clinical trial NCT01963481?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.